Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $194

Benzinga · 4d ago
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $184 to $194.